Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Cytokinetics, Incorporated (CYTK)

35.17   -1.01 (-2.79%) 03-22 14:37
Open: 36.02 Pre. Close: 36.18
High: 37.445 Low: 35
Volume: 338,033 Market Cap: 3,511(M)

Technical analysis

as of: 2023-03-22 2:16:37 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 48.43     One year: 53.54
Support: Support1: 34.4    Support2: 28.62
Resistance: Resistance1: 41.46    Resistance2: 45.84
Pivot: 37.6
Moving Average: MA(5): 35.86     MA(20): 38.97
MA(100): 41.35     MA(250): 43.24
MACD: MACD(12,26): -1.9     Signal(9): -1.7
Stochastic oscillator: %K(14,3): 13.5     %D(3): 13.7
RSI: RSI(14): 36.6
52-week: High: 55.79  Low: 33.59
Average Vol(K): 3-Month: 954 (K)  10-Days: 1,209 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ CYTK ] has closed above bottom band by 23.3%. Bollinger Bands are 6.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 36.68 - 36.92 36.92 - 37.14
Low: 34.54 - 34.85 34.85 - 35.12
Close: 35.7 - 36.19 36.19 - 36.63

Company Description

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Headline News

Wed, 22 Mar 2023
Yousif Capital Management LLC Sells 13145 Shares of Cytokinetics ... - MarketBeat

Tue, 21 Mar 2023
CYTK (Cytokinetics Incorporated): Time to Pay Attention? - The Dwinnex

Tue, 21 Mar 2023
Teachers Retirement System of The State of Kentucky Invests $2.27 ... - MarketBeat

Mon, 20 Mar 2023
Peregrine Capital Management LLC increases its holdings in ... - Best Stocks

Sun, 19 Mar 2023
Peregrine Capital Management LLC Increases Stock Position in ... - MarketBeat

Sun, 19 Mar 2023
Robert I. Blum Sells 12500 Shares of Cytokinetics, Incorporated ... - Defense World

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 95 (M)
Shares Float 94 (M)
% Held by Insiders 1.2 (%)
% Held by Institutions 115.7 (%)
Shares Short 9,500 (K)
Shares Short P.Month 9,980 (K)

Stock Financials

EPS -4.06
EPS Est Next Qtl -0.39
EPS Est This Year -2.5
EPS Est Next Year -2.47
Book Value (p.s.) -1.14
Profit Margin (%) 0
Operating Margin (%) -342.8
Return on Assets (ttm) -21.9
Return on Equity (ttm) -572.2
Qtrly Rev. Growth -96.5
Gross Profit (p.s.) -1.54
Sales Per Share 0.99
EBITDA (p.s.) -3.35
Qtrly Earnings Growth 0
Operating Cash Flow -300 (M)
Levered Free Cash Flow -127 (M)

Stock Valuations

PE Ratio -8.78
PEG Ratio -0.6
Price to Book value -31.17
Price to Sales 35.74
Price to Cash Flow -11.29

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.